Angiogenesis is the formation of new capillaries on existing blood vessels, which is a dynamic process. Under normal circumstances, angiogenesis is very rare in adults, but in patients with malignant tumors, angiogenesis provides a steady stream of nutrients for the growth of tumor cells. Therefore, anti-angiogenesis is of great significance for cancer therapy. However, abnormal glucose metabolism in cancer cells promotes tumor progression by secreting some pro-angiogenic factors, mediating endothelial cell proliferation, migration, and altering vascular permeability. Endothelial cells coat the lining of blood vessels and are necessary for the exchange of nutrients and oxygen between blood flow and tumor tissue. Therefore, CD BioGlyco can provide analytics services on the relationship between the glucose metabolism status of tumor endothelial cells and the relationship between glucose metabolism reprogramming and angiogenesis, which can help the development of anti-angiogenic therapeutic methods.

Fig. 1 Characteristics of glucose metabolism in tumor endothelial cells (Du W, et al., 2021)

What We Do

• Analysis of the relationship between tumor endothelial cell metabolism and angiogenesis

Angiogenesis is a complex process that contains multiple steps and is affected by multiple factors, including pro-angiogenic factors, angiogenesis-inhibiting factors, endothelial cell metabolism, etc. Studying endothelial cell vascular metabolism can provide evidence for the development of anti-angiogenic drugs.

We can provide the following specific services, including but not limited to:

• Analysis of the status of endothelial cell glucose metabolism
• Analysis of the effects of glucose metabolites on endothelial cell metabolism
• Analysis of the effects of glucose metabolism-related enzymes on endothelial cell growth and proliferation

• Analysis of the effect of glucose metabolites on angiogenesis

Cancer cell glucose metabolites have demonstrated pro-angiogenic functions in a variety of cancers including pancreatic, colorectal, liver, breast, lung, and cervical cancers. We are able to provide the following specific analytical services based on published research results and customers’ research objectives.

• Analysis of the effects of glucose metabolites on the secretion of pro-angiogenic factors
• Analysis of the regulatory effect of glucose metabolites on pro-angiogenic signaling pathways

Our Advantages

• Based on the MOPCGM platform, we are able to conduct a comprehensive analysis of genomic, metabolomic, and proteomic data of normal endothelial cells and tumor-associated endothelial cells.
• We can integrate information about angiogenesis and other features of cancer to find innovative research directions.

Applications

• Development of tumor-specific anti-angiogenic drugs based on metabolic reprogramming of cancer cells.
• Discovery of biomarkers for efficacy and toxicity based on metabolic differences between tumor endothelial cells and normal endothelial cells.

CD BioGlyco can provide analysis services for the relationship between the glucose metabolism status of tumor endothelial cells and the relationship between glucose metabolism reprogramming and angiogenesis. Our experienced teams of scientists, researchers, and technicians provide a fast turnaround, and high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.

Reference:

1. Du W, et al. Endothelial Cell Glucose Metabolism and Angiogenesis. Biomedicines. 2021 Feb 3; 9(2): 147.